share_log

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

诺瓦瓦克斯医药 | DFAN14A：其他委托征集材料
美股SEC公告 ·  2024/05/13 13:15

Moomoo AI 已提取核心信息

Shah Capital Management, Inc., along with its affiliates, has filed a preliminary proxy statement with the SEC to solicit votes against the election of three Novavax, Inc. board members at the upcoming annual meeting on June 13, 2024. The hedge fund, which owns approximately 7.5% of Novavax and is one of its top three shareholders, is also urging stockholders to vote against certain company proposals, including executive compensation amendments. Shah Capital's actions follow a recent licensing agreement between Novavax and Sanofi, which boosted Novavax's stock by over 100%. The fund has been critical of Novavax's current management and marketing strategies, believing the company to be undervalued. Shah Capital has nominated two new board members to aid in turning around the company's fortunes. The fund highlights Novavax's strong IP portfolio and the potential market for non-mRNA protein vaccines, as acknowledged by the CDC's report on vaccine effectiveness.
Shah Capital Management, Inc., along with its affiliates, has filed a preliminary proxy statement with the SEC to solicit votes against the election of three Novavax, Inc. board members at the upcoming annual meeting on June 13, 2024. The hedge fund, which owns approximately 7.5% of Novavax and is one of its top three shareholders, is also urging stockholders to vote against certain company proposals, including executive compensation amendments. Shah Capital's actions follow a recent licensing agreement between Novavax and Sanofi, which boosted Novavax's stock by over 100%. The fund has been critical of Novavax's current management and marketing strategies, believing the company to be undervalued. Shah Capital has nominated two new board members to aid in turning around the company's fortunes. The fund highlights Novavax's strong IP portfolio and the potential market for non-mRNA protein vaccines, as acknowledged by the CDC's report on vaccine effectiveness.
Shah Capital Management, Inc. 及其附属公司已向美国证券交易委员会提交了初步委托书，要求在即将于2024年6月13日举行的年会上投票反对选举三名Novavax, Inc.董事会成员。该对冲基金拥有Novavax约7.5％的股份，是其前三名股东之一。该对冲基金还敦促股东投票反对某些公司提案，包括高管薪酬修正案。Shah Capital的行动是在Novavax和赛诺菲最近达成许可协议之后采取的，该协议使Novavax的股票上涨了100％以上。该基金一直对Novavax目前的管理和营销策略持批评态度，认为该公司的估值被低估了。Shah Capital已提名两名新的董事会成员，以帮助扭转公司的命运。正如疾病预防控制中心关于疫苗有效性的报告所承认的那样，该基金突显了Novavax强大的知识产权组合和非mRNA蛋白疫苗的潜在市场。
Shah Capital Management, Inc. 及其附属公司已向美国证券交易委员会提交了初步委托书，要求在即将于2024年6月13日举行的年会上投票反对选举三名Novavax, Inc.董事会成员。该对冲基金拥有Novavax约7.5％的股份，是其前三名股东之一。该对冲基金还敦促股东投票反对某些公司提案，包括高管薪酬修正案。Shah Capital的行动是在Novavax和赛诺菲最近达成许可协议之后采取的，该协议使Novavax的股票上涨了100％以上。该基金一直对Novavax目前的管理和营销策略持批评态度，认为该公司的估值被低估了。Shah Capital已提名两名新的董事会成员，以帮助扭转公司的命运。正如疾病预防控制中心关于疫苗有效性的报告所承认的那样，该基金突显了Novavax强大的知识产权组合和非mRNA蛋白疫苗的潜在市场。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Portage Biotech
    PRTG
    -- 9.600
    莱斯康制药
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点